Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.67 |
| ▸ | FBP1 | P09467 | 4/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230930 | 0.96 | EGFR (0.67) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4228349 | 0.94 | KDR (0.68) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4231125 | 0.94 | KDR (0.68) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL1418593 | 0.94 | EGFR (0.58) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4226683 | 0.93 | KDR (0.67) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4232040 | 0.93 | KDR (0.67) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL6502391 | 0.91 | EGFR (0.57) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL1419933 | 0.91 | FBP1 (0.70) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4226005 | 0.90 | KDR (0.71) | EGFRFBP1ERBB2ERBB4KDR | |
| SCHEMBL4230323 | 0.90 | KDR (0.71) | EGFRFBP1ERBB2ERBB4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | EGFR 2063/4885FBP1 2020/4885ERBB2 3690/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | EGFR 2063/4885FBP1 2020/4885ERBB2 3690/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | EGFR 1367/4885FBP1 1245/4885ERBB2 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.